文献速递皮肤肿瘤

Avelumab联合西妥昔单抗治疗不可切除III/IV期皮肤鳞状细胞癌:AliCe单臂多中心II期DeCOG试验的疗效与安全性

Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial.
PubMed 文献 · Br J Dermatol · 2025-01-01

AliCe单臂多中心II期试验评估avelumab联合西妥昔单抗治疗晚期cSCC,49例可评估患者客观缓解率41%(95%CI 27-56),中位无进展生存8.4个月、总生存23.1个月,≥3级治疗相关不良事件20%,生活质量改善。

要点

  • avelumab联合西妥昔单抗在晚期cSCC中客观缓解率41%,含11例完全缓解。
  • 初治患者客观缓解率46%,经治患者29%,其中2例既往PD-1抑制剂治疗后仍缓解。
  • 会阴生殖部位原发cSCC患者客观缓解率36%,含4例完全缓解。

核心结论

  • avelumab联合西妥昔单抗在晚期cSCC中显示鼓舞人心的临床活性,包括会阴生殖部位原发或抗PD-1单药治疗后进展的困难亚组。

研究设计与样本

  • 单臂多中心II期DeCOG试验纳入晚期cSCC患者,允许既往系统治疗,给予avelumab 10 mg kg-1 Q2W联合西妥昔单抗500 mg m-2 Q2W,最长1年。
  • 主要终点为客观缓解,预设亚组为治疗线数和原发肿瘤部位(会阴生殖部位/其他部位)。
  • 52例入组,49例至少接受1剂治疗。

主要发现

  • 20例达到客观缓解(41%,95%CI 27-56),其中9例部分缓解、11例完全缓解。
  • 初治患者(n=35)客观缓解率46%(95%CI 29-63),经治患者29%(95%CI 8-58),14例经治中4例缓解,2例既往接受过PD-1抑制剂。
  • 14例会阴生殖部位原发cSCC中5例客观缓解(36%,95%CI 13-65),含4例完全缓解。
  • 中位随访35个月,中位无进展生存8.4个月,中位总生存23.1个月。
  • ≥3级治疗相关不良事件见于10例(20%),7例(14%)发生严重治疗相关不良事件,2例因药物相关毒性停药;生活质量改善,尤其会阴生殖部位原发患者。

关键数值与推荐

  • 客观缓解率41%(95%CI 27-56),完全缓解11例、部分缓解9例。
  • 初治患者客观缓解率46%(95%CI 29-63),经治患者29%(95%CI 8-58)。
  • 会阴生殖部位原发患者客观缓解率36%(95%CI 13-65)。
  • 中位无进展生存8.4个月,中位总生存23.1个月。
  • ≥3级治疗相关不良事件20%,严重治疗相关不良事件14%。

临床怎么用

  • 对于晚期cSCC,尤其会阴生殖部位原发或抗PD-1单药治疗后进展者,可考虑avelumab联合西妥昔单抗。
  • 治疗前应评估患者能否耐受至少12周治疗, carefully selected 患者可能获益更多。
  • 治疗期间需监测治疗相关不良事件,多数为1-2级,但仍有20%出现≥3级事件。

局限性

  • 单臂II期设计,无随机对照,结论需进一步验证。
  • 样本量较小(49例可评估),亚组分析例数有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In cutaneous squamous cell carcinoma (cSCC), programmed cell death protein 1 (PD-1) and epidermal growth factor receptor (EGFR) inhibitors are effective in a considerable proportion of patients. However, there is an unmet medical need for patients with perianogenital cSCC or cSCC refractory to PD-1 therapy. OBJECTIVES: To evaluate the combination avelumab (programmed death ligand 1 inhibitor) and cetuximab (EGFR inhibitor) in people with advanced cSCC treated for up to 1 year. METHODS: This multicentre phase II trial enrolled patients with advanced cSCC (prior systemic therapy allowed) to receive avelumab (10 mg kg-1 Q2W) plus cetuximab (500 mg m-2 Q2W) for up to 1 year. The primary endpoint was objective response. Predefined subgroups were line of therapy and localization of the primary tumour (perianogenital/other locations). RESULTS: Of 52 enrolled patients, 49 received at least 1 treatment dose. Of these patients, 20 achieved an objective response [41%, 95% confidence interval (CI) 27-56; 9 partial responses/11 complete responses (CRs)]. While treatment-naïve patients (n = 35) achieved a higher objective response rate (46%, 95% CI 29-63) than those who were pretreated (29%, 95% CI 8-58), 4 of 14 pretreated patients experienced an objective response, 2 with prior PD-1 inhibition. Five of 14 patients with perianogenital cSCC achieved an objective response (36%, 95% CI 13-65), including 4 CRs. At a median follow-up of 35 months, median progression-free and overall survival were 8.4 and 23.1 months, respectively. Grade 1 and 2 treatment-related adverse events (TRAEs) were common, while grade ≥ 3 events occurred in only 10 patients (20%) and 7 experienced serious TRAEs (14%); 2 discontinued treatment due to drug-related toxicity. Notably, quality of life improved, especially in patients with perianogenital primaries. CONCLUSIONS: Avelumab in combination with cetuximab demonstrates encouraging clinical activity in advanced cSCC, including patients with challenging subgroups such as perianogenital primaries or those with disease that has progressed on anti-PD-1 monotherapy. This is especially true when patients are carefully selected for their ability to undergo treatment for at least 12 weeks. Cutaneous squamous cell carcinoma (cSCC) is a type of skin cancer that can be hard to treat. Sometimes, combining different medicines can help. Some drugs work well for many patients, but over time, the cancer can stop responding to these drugs. So, better treatments are needed. This study looked at two drugs, avelumab and cetuximab, used together in people with advanced cSCC. They were treated for up to 1 year. We wanted to see how well this treatment worked. Out of 49 patients who took at least one dose, 20 showed a positive response to the treatment. Patients who had never had treatment before responded better than those who had been treated before. The patients were followed for almost 3 years. On average, the cancer did not get worse for more than 8 months. After treatment, patients lived for almost 2 years. There were some side effects from the treatment. Two patients had to stop because of serious side effects. But overall, patients reported a better quality of life. Our results suggest that this treatment could be a good option for people with advanced cSCC. When patients can handle the treatment, it may also improve how they feel day-to-day.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Becker JC, Gesierich AH, Leiter U, et al. Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial. Br J Dermatol. 2025. PMID: 40713865. doi:10.1093/bjd/ljaf303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。